Accentia Faces Investor Suit Over Lymphoma Vaccine

Law360, Los Angeles (July 29, 2013, 6:05 PM EDT) -- The directors of Accentia Biopharmaceuticals Inc. subsidiary Biovest International Inc. lied to investors about the performance of a non-Hodgkin's lymphoma treatment vaccine that Biovest was developing, artificially inflating both companies' stock prices, according to a securities class action filed Friday in Florida federal court.

Biovest management said the vaccine was successful in a key clinical trial even though the U.S. Food and Drug Administration repeatedly said that the results wouldn't support a license application, according to the suit filed by three stockholders.

After the truth about...
To view the full article, register now.




Case Information

Case Title

Hill et al v. Accentia Biopharmaceuticals, Inc. et al

Case Number



Florida Middle

Nature of Suit

Stockholders Suits


Steven D. Merryday

Date Filed

July 26, 2013

Law Firms

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.